KARO BIO AND ZYDUS CADILA extend RESEARCH AGREEMENT

Stockholm, March 21, 2011 – Karo Bio AB (publ) (Reuters: KARO.ST) and Zydus Cadila have agreed to extend their research collaboration with the purpose to discover and develop novel anti-inflammatory drug compounds which affect glucocorticoid receptors in a selective manner.In early 2008, Karo Bio and the Indian pharmaceutical company Zydus Cadila initiated a three-year collaboration. The parties have now agreed to extend the collaboration for one year. The aim of the collaboration is to design novel, selective glucocorticoids for the treatment of inflammatory diseases that have as powerful